Kura Oncology KURA Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's stock issuance proceeds?
- Kura Oncology (KURA) reported stock issuance proceeds of $69K in Q1 2026.
- How has Kura Oncology's stock issuance proceeds changed year-over-year?
- Kura Oncology's stock issuance proceeds decreased by 51.7% year-over-year, from $143K to $69K.
- What is the long-term trend for Kura Oncology's stock issuance proceeds?
- Over 3 years (2021 to 2025), Kura Oncology's stock issuance proceeds has grown at a -26.0% compound annual growth rate (CAGR), from $4.43M to $1.79M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.